| Avesthagen arm inks MoU with Biotech Corp |
| BS Reporter / Bangalore June 3, 2007 |
| AvestaBiotherapeutic and Research (ABRPL), a joint venture between Avesthagen and Meditab Specialities, a part of Cipla group, has signed a memorandum of understanding (MoU) with Malaysian Biotechnology Corporation (MBC) for manufacture of biosimilars. Villoo Morawala Patell, managing director, Avesthagen said, ABRPL, in order to achieve early market access, has identified MBC, which will enable ABRPL to enhance the infrastructure needs with an objective to accelerate its 11 biosimilar (are similar biological products) product development programme. MBC is an agency under the purview of the Malaysian ministry of science, technology and innovation and owned wholly by the ministry of finance. The agency identifies value propositions in the biotech sector in both research and development and commerce and supports these ventures via financial assistance, and developmental and facilitation services. The agency is desirous of facilitating ABRPL |
